News Focus
News Focus
Post# of 257257
Next 10
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

Re: DewDiligence post# 30200

Saturday, 07/15/2006 6:16:54 PM

Saturday, July 15, 2006 6:16:54 PM

Post# of 257257
Abstract on antithrombin in cardiopulmonary bypass:

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=Abstract&list_...

>>
Antithrombin reduces monocyte and neutrophil
CD11b up-regulation in addition to blocking platelet
activation during extracorporeal circulation

Transfusion. 2006 Jul;46(7):1130-7.

Rinder CS, Rinder HM, Smith MJ, Fitch JC, Tracey JB, Chandler WL, Rollins SA, Smith BR.

Department of Anesthesiology, Yale University School of Medicine, New Haven, Connecticut.

Patients undergoing cardiac surgery requiring cardiopulmonary bypass develop a systemic inflammatory reaction. Antithrombin III (AT) has anticoagulant effects but also shows evidence of anti-inflammatory activity.

The aim of this study was to examine whether exogenous AT could reduce white blood cell activation
(CD11b up regulation or elastase release), in addition to inhibiting platelet (PLT) activation and fibrin generation, during simulated cardiopulmonary bypass (sCPB), undertaken in the absence of endothelium.

sCPB was carried out with minimally heparinized (2 U/mL) human blood for 90 minutes in controls and with supplementation by low-dose (1 U/mL) and high-dose (5 U/mL) AT.

High-dose AT blunted thrombin generation during sCPB (prothrombin fragment 1.2); both doses significantly inhibited thrombin activity (fibrinopeptide A). Complement activation (C3a and C5b-9) was unaffected by AT. High-dose AT inhibited PLT activation (P-selectin expression and P-selectin-dependent monocyte-PLT conjugate formation).

AT supplementation at the higher dose significantly abrogated monocyte and neutrophil CD11b up regulation and neutrophil elastase release. In addition to anticoagulant and anti-PLT effects, pharmacologic AT doses significantly blunted monocyte and neutrophil CD11b up regulation and neutrophil elastase release during sCPB, independent of endothelial effects.

These data provide evidence for the direct anti-inflammatory activity of AT that has clinical relevance for CPB complications.
<<

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now